AI Takeaway
Incyte Corporation delivered a transformational FY2025, with revenue surging 21.2% to $5.14B and net income skyrocketing to $1.29B (from $32.6M), driven by a dramatic reduction in R&D spending and strong commercial momentum, resulting in a 29.5% operating margin.
Revenue
$5.14B
++21.22% YoY
EPS (Basic)
$6.59
++4018.75% YoY
Operating Income
$1.51B
++2368.56% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-K filing
Total revenue grew 21.2% year-over-year to $5.14B in FY2025, up from $4.24B in the prior year, reflecting strong commercial execution across Incyte's marketed product portfolio.
Source: Source: 10-K Income Statement
Operating income surged 2,368.6% to $1.51B, and net income jumped 3,846.8% to $1.29B, as the company achieved a 29.5% operating margin compared to just 1.4% in the prior year, reflecting significant operating leverage.
Source: Source: 10-K Income Statement
R&D expenses declined 21.4% to $2.05B from $2.61B in the prior year, a reduction of approximately $557M, which was the primary driver of the dramatic improvement in operating and net income.
Source: Source: 10-K Income Statement
2 more insights available
Upgrade to unlockDespite the significant reduction in R&D spend, Incyte remains heavily dependent on its pipeline for future growth. Any clinical trial failures or regulatory setbacks could materially impair long-term revenue prospects. The $2.05B still invested in R&D underscores the high-stakes nature of drug development.
Source: Source: 10-K Income Statement
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $1.80 versus the $1.97 analyst consensus — a -8.5% miss for FY2025.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $5.14B | $4.24B | +21.22% |
Cost of Revenue | $372.13M | $312.07M | +19.25% |
Operating Income | $1.51B | $61.37M | +2368.56% |
Net Income | $1.29B | $32.6M | +3846.78% |
EPS (Basic) | $6.59 | $0.16 | +4018.75% |
EPS (Diluted) | $6.41 | $0.15 | +4173.33% |
R&D Expense | $2.05B | $2.61B | -21.36% |
SG&A Expense | $1.38B | $1.24B | +10.79% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $6.96B | $5.44B | +27.80% |
Current Assets | $5.02B | $3.24B | +55.11% |
Total Liabilities | $1.79B | $2B | -10.33% |
Current Liabilities | $1.52B | $1.64B | -7.72% |
Stockholders' Equity | $5.17B | $3.45B | +49.89% |
Cash & Equivalents | $3.1B | $1.69B | +83.54% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.41B | $335.34M | +321.52% |
Investing Cash Flow | $-102.61M | $157.52M | -165.14% |
Financing Cash Flow | $101.04M | $-2.02B | +105.00% |
Share Buybacks | $0 | $2B | -100.00% |
D&A | $93.29M | $89.25M | +4.52% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | 29.5% | 1.4% | +28.02% |
Net Margin | 25.0% | — | — |
ROE | 24.9% | — | — |
ROA | 18.5% | — | — |
Current Ratio | $3.316 | — | — |
Debt to Equity | $0.346 | — | — |
Other companies in Biotechnology
Incyte had a standout FY2025, with revenue growing 21.2% to $5.14B and net income surging to $1.29B from just $32.6M in the prior year. The dramatic improvement was largely driven by a $557M reduction in R&D expenses, which pushed operating margin to 29.5%.
Incyte's earnings surged primarily because R&D expenses fell 21.4% to $2.05B, down from $2.61B in the prior year, while revenue grew 21.2%. This combination of higher revenue and lower costs drove net income up 3,846.8% and diluted EPS from $0.15 to $6.41.
Incyte's financial health is strong: cash and equivalents grew 83.5% to $3.10B, the current ratio is 3.32, and debt-to-equity is a conservative 0.35. Total liabilities declined 10.3% while stockholders' equity grew 49.9% to $5.17B.
No, Incyte did not repurchase any shares in FY2025, a significant reversal from the prior year when it spent $2.00B on buybacks. The company instead focused on building its cash position, which grew to $3.10B.
Key risks include pipeline execution risk given Incyte's continued heavy R&D investment of $2.05B, revenue concentration in a limited set of branded products that face potential generic competition, and rising SG&A costs that grew 10.8% to $1.38B. Investors should also monitor how management deploys the growing $3.10B cash balance.